Strategic assets sale Seelos recently sold select assets to GLD Partners through Chapter 11 proceedings, indicating a divestiture of non-core assets and potential opportunities for partners to acquire or license remaining programs or IP related to CNS disorders and rare diseases.

Clinical-stage focus As a clinical-stage biopharma with late-stage assets targeting psychiatric and movement disorders, Seelos presents opportunities for collaborations, licensing, or co-development deals with firms specializing in CNS therapeutics, orphan diseases, and ketamine-based treatment platforms.

Public financing history Recent public offering and ongoing investor communications suggest readiness for strategic partnerships and capital-efficient collaborations; BD teams can pursue joint ventures or milestone-driven deals leveraging Seelos’ pipeline and public market footprint.

Leadership and BD activity Appointment of a new Chairman to lead strategic partnerships signals an active business development posture; engage early to align on potential partnerships, collaborations, or licensing of late-stage assets and related technologies.

Tech and data leverage Seelos employs cloud and data tools (AWS, analytics platforms) to support its operations; potential upsell or collaboration opportunities include data-driven trial design, real-world evidence generation, or technology partnerships to optimize CNS trial workflows.